Tango Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
TNGX$24.30+6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Collaboration revenue | $— | $53,811 | $— | $62,384 |
| Operating expenses: | ||||
| Research and development | 48,929 | 30,815 | 119,663 | 100,064 |
| General and administrative | 29,187 | 8,924 | 67,008 | 31,745 |
| Total operating expenses | 78,116 | 39,739 | 186,671 | 131,809 |
| Operating income (loss) | (78,116) | 14,072 | (186,671) | (69,425) |
| Other income: | ||||
| Interest income | 7,151 | 1,097 | 13,051 | 3,950 |
| Other income, net | 2,571 | 705 | 4,373 | 2,689 |
| Total other income, net | 9,722 | 1,802 | 17,424 | 6,639 |
| Pretax income (loss) | (68,394) | 15,874 | (169,247) | (62,786) |
| Benefit from (provision for) income taxes | — | 10 | (2) | (59) |
| Net income (loss) | $(68,394) | $15,884 | $(169,249) | $(62,845) |
| Net income (loss) per common share – basic | $(0.39) | $0.14 | $(1.08) | $(0.57) |
| Weighted average number of common shares outstanding – basic | 173,930,255 | 110,966,345 | 157,176,327 | 110,761,673 |
| Net income (loss) per common share – diluted | $(0.39) | $0.13 | $(1.08) | $(0.57) |
| Weighted average number of common shares outstanding – diluted | 173,930,255 | 117,782,074 | 157,176,327 | 110,761,673 |
| Net income (loss) | $(68,394) | $15,884 | $(169,249) | $(62,845) |
| Other comprehensive income (loss): | ||||
| Unrealized gain (loss) on marketable securities | (3,875) | 27 | (4,732) | (215) |
| Comprehensive income (loss) | $(72,269) | $15,911 | $(173,981) | $(63,060) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.